Innova Captab

Innova Captab R&D / Revenue

The R&D to Revenue Ratio of Innova Captab (INNOVACAP.NS) as of Nov 22, 2026 is 0.44 %. In the previous year, R&D to Revenue Ratio was 0.53 % — a change of -17.19% (lower).

R&D / Revenue

0.44 %

YoY

-17.19%

Last updated:

R&D to Revenue Ratio of Innova Captab is 2026 0.44 % . R&D to Revenue Ratio of Innova Captab was 2025 0.53 % . It decreases by -17.19% lower compared to the previous year.

The Innova Captab R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2024
0.53 INR
Jan 1, 2025
0.53 INR
Jan 1, 2026
0.44 INR
The Innova Captab R&D / Revenue history
YEARR&D / RevenueYoY
0.44 %-17.19%
0.53 %-0.49%
0.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innova Captab Stock analysis

What does Innova Captab do? Innova Captab Ltd generates revenue through its CDMO business, which offers research, product development, and manufacturing services to clients in the pharmaceutical sector. The company also earns from its domestic branded generics business, developing, manufacturing, and distributing generic formulation products under its own brand names across India via online and offline channels. Additionally, Innova Captab sells its generic drug products through various e-commerce pharmacy sites. The company's diversified portfolio includes tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. Its international branded generic product business focuses on exporting branded generic products globally. Innova Captab's primary customers are pharmaceutical companies seeking CDMO services, Indian consumers purchasing generic medicines through retail and online pharmacies, and international buyers of branded generic products. The domestic market segment is served through branded generics sold under the company's own brand names, while the international segment targets global markets for branded generic drug exports. The company's value chain spans research and development, manufacturing, drug distribution, marketing, and exports, ensuring comprehensive coverage across the pharmaceutical industry. The company's product segments include CDMO services, domestic branded generics, and international branded generics. CDMO services are provided to pharmaceutical firms requiring outsourced research and manufacturing. Domestic branded generics are marketed in India under the company's brand names through both online and offline channels. International branded generics are exported to global markets, leveraging the company's manufacturing capabilities and product portfolio. Innova Captab's business model integrates all stages of the pharmaceutical value chain, from R&D to exports, to deliver a full-service solution for its clients and customers. Innova Captab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innova Captab stock

R&D to Revenue Ratio of Innova Captab is 0.44 % in 2026.

R&D to Revenue Ratio of Innova Captab changed from 0.53 % to 0.44 %, representing a -17.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Innova Captab since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Innova Captab with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Innova Captab

All Key Metrics — Innova Captab